All In Biotech

Drug Trial Radar · NCT05011305

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

189

Actual

Start

Aug 18, 2021

Primary completion

Sep 12, 2025

Study completion Sep 12, 2025

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

Conditions

  • Nonalcoholic Steatohepatitis
  • Fibrosis

Interventions

  • Saroglitazar Magnesium 2 mgDrug

    Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

  • Saroglitazar Magnesium 4 mgDrug

    Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

  • PlaceboDrug

    Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resolution of steatohepatitis with no worsening of fibrosisTime frame: 52 Weeks/EOT

Locations

129 sites in 4 countries. Site status is shown where the registry gives one.

  • Zydus US032

    Birmingham, Alabama

  • Zydus US079

    Homewood, Alabama

  • Zydus US047

    Phoenix, Arizona

  • Zydus US025

    Tucson, Arizona

  • Zydus US087

    Tucson, Arizona

  • Zydus US029

    Tucson, Arizona

  • Zydus US118

    Chula Vista, California

  • Zydus US041

    Fresno, California

  • Zydus US111

    Gardena, California

  • Zydus US013

    Huntington Park, California

  • Zydus US065

    La Jolla, California

  • Zydus US094

    Lancaster, California

  • Zydus US080

    Long Beach, California

  • Zydus US090

    Long Beach, California

  • Zydus US022

    Los Angeles, California

  • Zydus US062

    Los Angeles, California

  • Zydus US023

    Murrieta, California

  • Zydus US052

    Orange, California

  • Zydus US012

    Panorama City, California

  • Zydus US039

    Aurora, Colorado

  • Zydus US122

    Clearwater, Florida

  • Zydus US057

    Fort Myers, Florida

  • Zydus US108

    Hallandale, Florida

  • Zydus US096

    Hialeah Gardens, Florida

  • Zydus US003

    Lakeland, Florida

  • Zydus US016

    Lakewood Rch, Florida

  • Zydus US125

    Largo, Florida

  • Zydus US001

    Maitland, Florida

  • Zydus US124

    Maitland, Florida

  • Zydus US007

    Miami, Florida

  • Zydus US024

    Miami, Florida

  • Zydus US034

    Miami, Florida

  • Zydus US038

    Miami, Florida

  • Zydus US121

    Miami, Florida

  • Zydus US054

    Miami, Florida

  • Zydus US098

    Miami Lakes, Florida

  • Zydus US099

    Naples, Florida

  • Zydus US081

    Ocala, Florida

  • Zydus US085

    Orlando, Florida

  • Zydus US104

    Port Orange, Florida

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.